Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Gains from Investment Securities (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Gains from Investment Securities for 4 consecutive years, with $5216.0 as the latest value for Q3 2024.

  • On a quarterly basis, Gains from Investment Securities rose 57.87% to $5216.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $5216.0, a 57.87% increase, with the full-year FY2023 number at $2.4 million, down 29.27% from a year prior.
  • Gains from Investment Securities was $5216.0 for Q3 2024 at Actinium Pharmaceuticals, down from $5420.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.4 million in Q4 2022 to a low of $1000.0 in Q4 2023.
  • A 4-year average of $242208.8 and a median of $21000.0 in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 15336.36% in 2022, then tumbled 99.97% in 2023.
  • Actinium Pharmaceuticals' Gains from Investment Securities stood at $22000.0 in 2021, then surged by 15336.36% to $3.4 million in 2022, then crashed by 99.97% to $1000.0 in 2023, then skyrocketed by 421.6% to $5216.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Gains from Investment Securities are $5216.0 (Q3 2024), $5420.0 (Q2 2024), and $2000.0 (Q1 2024).